Abstract 200P
Background
TITAN demonstrated that APA + ADT improves radiographic progression-free survival and overall survival over placebo (PBO) + ADT in patients (pts) with mCSPC, including those with low- and high-volume disease, previous docetaxel use, and prior treatment for localized disease (Chi KN N Engl J Med 2019). The likelihood of meaningful deterioration in pt-reported pain and fatigue in TITAN is explored.
Methods
mCSPC pts were randomized 1:1 to receive either APA (240 mg daily; n = 525) or PBO (n = 527), in addition to continuous ADT; each treatment cycle (C) was 28 days. Pain and fatigue were assessed using the Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory (BFI), at baseline and averaged over 7 consecutive days (D) (D -6 through D1 of each C). General estimating equations for logistic regression were used to estimate treatment-related differences in likelihood of worsening in pain or fatigue scores (worsening of ≥ 2 points in items from BPI-SF and BFI).Table:
200P
Pain | Fatigue | |||
---|---|---|---|---|
BPI-SF | BFI | |||
Item | OR* | p† | OR* | p† |
Worst pain or fatigue, past 24 hr | 0.84 | 0.087 | 1.05 | 0.693 |
Least pain, past 24 hr | 0.78 | 0.062 | NA | NA |
Pain on average | 0.82 | 0.057 | NA | NA |
Pain or fatigue right now | 0.84 | 0.169 | 0.98 | 0.863 |
Average pain score | 0.80 | 0.068 | NA | NA |
Pain or fatigue interference: | ||||
General activity | 0.83 | 0.151 | 1.02 | 0.849 |
Mood | 0.73 | 0.015 | 0.87 | 0.311 |
Walking | 0.82 | 0.129 | 0.93 | 0.549 |
Normal work | 0.86 | 0.232 | 1.00 | 0.976 |
Relations | 0.78 | 0.056 | 0.87 | 0.296 |
Sleep | 0.77 | 0.044 | NA | NA |
Enjoyment of life | 0.81 | 0.106 | 0.92 | 0.528 |
Overall interference score of pain or fatigue | 0.79 | 0.032 | 0.95 | 0.640 |
Usual fatigue, past 24 hr | NA | NA | 0.99 | 0.9044 |
hr, hours; NA, not on assessment; OR, adjusted odds ratio.
*Data from all time points, including baseline patient-reported outcome score and stratification factors.
†Nominal p-value, no adjustments of multiplicity.
Results
Median scores for pain (APA, 1.14; PBO, 1.00) and fatigue (APA, 1.29; PBO 1.43) on 0-10 severity scales indicated all pts were relatively asymptomatic at baseline. Pts treated with APA vs PBO consistently scored favorably in all BPI-SF pain severity– and pain interference–related questions, and had significantly lower risk of worsening pain interference with mood (p = 0.015), sleep (p = 0.044), and overall pain interference (p = 0.032; Table). Reduced risk of overall pain interference was observed by C18. In general, pt experience with fatigue was similar with APA and PBO (Table).
Conclusions
In a broad population of pts with mCSPC in TITAN, no additional pt-reported fatigue was observed with the addition of APA or PBO to ADT. Pts reported consistently favorable pain scores and less interference from pain in their daily lives with APA.
Clinical trial identification
NCT02489318.
Editorial acknowledgement
Editorial assistance was provided by Patricia McChesney, PhD, CMPP, of Parexel (Hackensack, NJ), and was funded by Janssen Research & Development.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
B.H. Chung: Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen (USA & Korea); Research grant / Funding (self): Bayer (Germany); Research grant / Funding (self): Pfizer (USA); Research grant / Funding (self): AstraZeneca (UK); Research grant / Funding (self): Roche (Switzerland); Research grant / Funding (self): Myovant Sciences GmbH (Australia); Travel / Accommodation / Expenses: Astellas (Korea); Travel / Accommodation / Expenses: Ipsen (Korea); Travel / Accommodation / Expenses: JW Pharma (Korea); Travel / Accommodation / Expenses: Takeda (Korea); Travel / Accommodation / Expenses: Handok (Korea); Travel / Accommodation / Expenses: Amgen (Korea). K. McQuarrie: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Bjartell: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Janssen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Incyte; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Ferring; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: IPSEN; Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Officer / Board of Directors: LIDDS Pharma; Research grant / Funding (self), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Officer / Board of Directors, Non-remunerated activity/ies: Glactone Pharma/Development ; Shareholder / Stockholder / Stock options: WntResearch. S. Chowdhury: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Johnson & Johnson; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Clovis. Á. Juárez Soto: Advisory / Consultancy, Speaker Bureau / Expert testimony, Non-remunerated activity/ies, Publication Steering Committee TITAN & IP Clinical Trial SPARTAN: Janssen. A.S. Merseburger: Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Janssen Cilag; Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Astellas Pharma; Travel / Accommodation / Expenses, Non-remunerated activity/ies, support for clinical trial conduct: Roche. H. Uemura: Speaker Bureau / Expert testimony, Research grant / Funding (self): Janssen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Takeda; Research grant / Funding (self): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono/BMS; Research grant / Funding (self): Taiho; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Novartis. R. Given: Speaker Bureau / Expert testimony: Janssen. B. Miladinovic: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. N. Li: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. S. Hudgens: Full / Part-time employment: Clinical Outcomes Solutions; Travel / Accommodation / Expenses: Janssen Research & Development. L. Floden: Full / Part-time employment: Clinical Outcomes Solutions; Travel / Accommodation / Expenses: Janssen Research & Development. A. Lopez-Gitlitz: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K.N. Chi: Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Janssen; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Astellas; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Essa ; Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Sanofi; Travel / Accommodation / Expenses, Institutional: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses, Institutional: AstraZeneca. N. Agarwal: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Advisory / Consultancy: Bristol Myers Squibb; Advisory / Consultancy: Bayer; Advisory / Consultancy: Clovis; Advisory / Consultancy: Eisai; Advisory / Consultancy: Exelixis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Ely Lilly; Advisory / Consultancy: Foundation One; Advisory / Consultancy: Genentech; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Merck; Advisory / Consultancy: Medivation; Advisory / Consultancy: Novartis; Advisory / Consultancy: Nektar; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pharmacyclics. All other authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract